Literature DB >> 30735682

Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series.

Jenna May Kim1, Miguel A Materin2, Mario Sznol3, Harriet M Kluger3, Sarah Weiss3, Jessica Chow1, Kathleen Stoessel1, Ninani Kombo1, Lucian Del Priore1, Renelle Pointdujour-Lim4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30735682      PMCID： PMC6933747          DOI： 10.1016/j.ophtha.2019.01.031

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  5 in total

1.  Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort.

Authors:  C Maire; S Vercambre-Darras; P Devos; M D'Herbomez; S Dubucquoi; L Mortier
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-12-07       Impact factor: 6.166

2.  U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.

Authors:  Maitreyee Hazarika; Meredith K Chuk; Marc R Theoret; Sirisha Mushti; Kun He; Shawna L Weis; Alexander H Putman; Whitney S Helms; Xianhua Cao; Hongshan Li; Hong Zhao; Liang Zhao; Joel Welch; Laurie Graham; Meredith Libeg; Rajeshwari Sridhara; Patricia Keegan; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2017-01-13       Impact factor: 12.531

3.  Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome.

Authors:  Ryan K Wong; Jimmy K Lee; John J Huang
Journal:  Retin Cases Brief Rep       Date:  2012

4.  Cyclosporine for Dry Eye Associated With Nivolumab: A Case Progressing to Corneal Perforation.

Authors:  Alexander T Nguyen; Maxwell Elia; Miguel A Materin; Mario Sznol; Jessica Chow
Journal:  Cornea       Date:  2016-03       Impact factor: 2.651

5.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  Jedd D Wolchok; Vanna Chiarion-Sileni; Rene Gonzalez; Piotr Rutkowski; Jean-Jacques Grob; C Lance Cowey; Christopher D Lao; John Wagstaff; Dirk Schadendorf; Pier F Ferrucci; Michael Smylie; Reinhard Dummer; Andrew Hill; David Hogg; John Haanen; Matteo S Carlino; Oliver Bechter; Michele Maio; Ivan Marquez-Rodas; Massimo Guidoboni; Grant McArthur; Celeste Lebbé; Paolo A Ascierto; Georgina V Long; Jonathan Cebon; Jeffrey Sosman; Michael A Postow; Margaret K Callahan; Dana Walker; Linda Rollin; Rafia Bhore; F Stephen Hodi; James Larkin
Journal:  N Engl J Med       Date:  2017-09-11       Impact factor: 91.245
  5 in total
  11 in total

Review 1.  Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.

Authors:  Yu-Wen Zhou; Qian Xu; Yan Wang; Ruo-Lan Xia; Ji-Yan Liu; Xue-Lei Ma
Journal:  Int J Ophthalmol       Date:  2022-04-18       Impact factor: 1.779

Review 2.  Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.

Authors:  Shruthi Harish Bindiganavile; Nita Bhat; Andrew G Lee; Dan S Gombos; Nagham Al-Zubidi
Journal:  J Immunother Precis Oncol       Date:  2021-02-25

3.  Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience.

Authors:  Vidhya Karivedu; Ihab Eldessouki; Ahmad Taftaf; Zheng Zhu; Abouelmagd Makramalla; Nagla Abdel Karim
Journal:  Case Rep Oncol Med       Date:  2019-04-17

Review 4.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

Review 5.  Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Caberry W Yu; Matthew Yau; Natalie Mezey; Ishraq Joarder; Jonathan A Micieli
Journal:  Eye Brain       Date:  2020-11-03

6.  A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer.

Authors:  Kyung Woo Kim; Sentaro Kusuhara; Motoko Tachihara; Chihiro Mimura; Wataru Matsumiya; Makoto Nakamura
Journal:  Am J Ophthalmol Case Rep       Date:  2021-03-12

7.  Acute Bilateral Uveitis, Hypotony, and Cataracts Associated with Ipilimumab and Nivolumab Therapy: Optical Coherence Tomography Angiography Findings.

Authors:  Jessica C Lee; Ghadeer Al-Humimat; Karanjit S Kooner
Journal:  Case Rep Ophthalmol       Date:  2020-11-10

8.  Immune Checkpoint Inhibitor Treatment and Ophthalmologist Consultations in Patients with Malignant Melanoma or Lung Cancer-A Nationwide Cohort Study.

Authors:  Maria D'Souza; Mette Bagger; Mark Alberti; Morten Malmborg; Morten Schou; Christian Torp-Pedersen; Gunnar Gislason; Inge Marie Svane; Jens Folke Kiilgaard
Journal:  Cancers (Basel)       Date:  2021-12-23       Impact factor: 6.639

9.  Bilateral Exudative Retinal Detachments Associated with Nivolumab Immunotherapy.

Authors:  Radwan S Ajlan; Joey Luvisi; Connor Brass
Journal:  Case Rep Ophthalmol       Date:  2020-10-13

10.  Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review.

Authors:  Jacob S Heng; Jenna M Kim; D Kyle Jones; Kathleen M Stoessel; Sarah A Weiss; Mario Sznol; Harriet M Kluger; Scott D Walter; Niki A Silverstein; Renelle Pointdujour-Lim
Journal:  BMJ Open Ophthalmol       Date:  2022-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.